Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppe Schepisi

Showing results (41-50 of 66) with videos related to

Pageof 7
Sort By:
JCO Precision Oncology|February 1, 2022
Multimodal Approach to Outcome Prediction in Metastatic Castration-Resistant Prostate Cancer by Integrating Functional Imaging and Plasma DNA AnalysisVincenza Conteduca, Emanuela Scarpi, Federica Matteucci, et al.
BMC Medicine|February 1, 2022
Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxelGiorgia Gurioli, Vincenza Conteduca, Nicole Brighi, et al.
Frontiers in Oncology|October 19, 2020
Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell TumorsGiuseppe Schepisi, Vincenza Conteduca, Chiara Casadei, et al.
Frontiers in Oncology|June 27, 2022
Inflammatory Biomarkers for Outcome Prediction in Patients With Metastatic Testicular CancerSara Bleve, Maria Concetta Cursano, Chiara Casadei, et al.
The Prostate|April 22, 2017
Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abirateroneVincenza Conteduca, Orazio Caffo, Cristian Lolli, et al.
Scientific Reports|October 20, 2018
Plasma androgen receptor and serum chromogranin A in advanced prostate cancerVincenza Conteduca, Emanuela Scarpi, Samanta Salvi, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 29, 2024
Correlation of [<sup>68</sup>Ga]Ga-PSMA PET/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patientsEmilio Francesco Giunta, Paola Caroli, Emanuela Scarpi, et al.
Frontiers in Oncology|September 4, 2023
Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patientsAlberto Farolfi, Elisabetta Petracci, Giorgia Gurioli, et al.
Cancers|November 7, 2019
Plasma Androgen Receptor in Prostate CancerVincenza Conteduca, Giorgia Gurioli, Nicole Brighi, et al.
BMC Cancer|December 21, 2018
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancerVincenza Conteduca, Giorgia Gurioli, Lorena Rossi, et al.
Pageof 7

Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
JCO Precision Oncology|February 1, 2022
Multimodal Approach to Outcome Prediction in Metastatic Castration-Resistant Prostate Cancer by Integrating Functional Imaging and Plasma DNA AnalysisVincenza Conteduca, Emanuela Scarpi, Federica Matteucci, et al.
BMC Medicine|February 1, 2022
Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxelGiorgia Gurioli, Vincenza Conteduca, Nicole Brighi, et al.
Frontiers in Oncology|October 19, 2020
Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell TumorsGiuseppe Schepisi, Vincenza Conteduca, Chiara Casadei, et al.
Frontiers in Oncology|June 27, 2022
Inflammatory Biomarkers for Outcome Prediction in Patients With Metastatic Testicular CancerSara Bleve, Maria Concetta Cursano, Chiara Casadei, et al.
The Prostate|April 22, 2017
Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abirateroneVincenza Conteduca, Orazio Caffo, Cristian Lolli, et al.
Scientific Reports|October 20, 2018
Plasma androgen receptor and serum chromogranin A in advanced prostate cancerVincenza Conteduca, Emanuela Scarpi, Samanta Salvi, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 29, 2024
Correlation of [<sup>68</sup>Ga]Ga-PSMA PET/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patientsEmilio Francesco Giunta, Paola Caroli, Emanuela Scarpi, et al.
Frontiers in Oncology|September 4, 2023
Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patientsAlberto Farolfi, Elisabetta Petracci, Giorgia Gurioli, et al.
Cancers|November 7, 2019
Plasma Androgen Receptor in Prostate CancerVincenza Conteduca, Giorgia Gurioli, Nicole Brighi, et al.
BMC Cancer|December 21, 2018
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancerVincenza Conteduca, Giorgia Gurioli, Lorena Rossi, et al.
Pageof 7